Recombinant DNA technology has led to accelerating introduction of novel therapeutics for the treatment of haemophilia. This technology has driven the development of recombinant clotting factors, extended half-life clotting factors, alternative biologics to promote haemostasis and enabled the launch of the gene therapy era for haemophilia. At the core of this technology is the ability to study the structure and function of the native molecules and to apply rational bioengineering to overcome limitations to the existing therapies. Through the study of haemophilia-causing mutations, site-directed mutagenesis, detailed structural models and a wide repertoire of animal models, new bioengineering strategies are helping overcome some of the remaining limitations and challenges of traditional clotting factor concentrates. Some of these bioengineering strategies are now being partnered with improvements in vectorology leading to the first wave of successful gene therapy approaches. This study will review past and present bioengineered molecules that are advancing care for haemophilia as well as novel approaches that promise to continue to improve care and outcomes for patients with haemophilia.
| INTRODUC TI ON
The initial wave of recombinant clotting factors provided a recombinant facsimile of their plasma-derived counterparts with remarkably similar biochemical, pharmacokinetic and pharmacodynamics properties. 1 Recombinant clotting factors have consistent manufacturing and processing liberated from the uncertainties of securing source plasma with at least the potential for an unlimited supply. With increased supply, there has been an increase in the availability of clotting factors and increased utilization of prophylaxis in developed and developing countries. 2, 3 In many health systems, this has driven down the unit costs of replacement therapy and allowed for more aggressive prophylaxis regimens targeting higher trough levels and lower annualized bleed rates. 4 Extensive global safety reviews over the past 25 years have demonstrated no infectious pathogen transmission, no safety signals from adverse event reporting and no evidence of increased rate of inhibitors in previously treated patients (PTPs). 5, 6 The remaining challenges in the recombinant era include barriers to the adoption and adherence to prophylaxis. This can be attributed to the burden of a requirement for consistent venous access, time and costs of primary prophylaxis initiated in infants and young children and continued throughout adulthood. 7 In addition, recombinant factor VIII (rFVIII) products have not been shown to reduce the risk of inhibitor development among previously untreated patients (PUPs). 8 This "natural" immune response to exposure to a foreign protein has been observed for all plasma-derived (pdFVIII) and rFVIII products with some studies demonstrating a significantly increased rate for the rFVIII. 9 There is considerable variability among patients with respect to phenotypic and pharmacokinetic variability. Even among those who have benefitted from early introduction of continuous prophylaxis, annualized bleed rates are not zero for all patients with joint disease still appearing in young adults followed over 25-30 years. 10 Further improvements in outcome can be achieved if patients have better bleed control. This can occur through improved adherence, which can be facilitated through strategies that reduce | 69 PIPE the burden of administration-reduced dosing frequency, increased availability at reduced cost and application of alternative modes of delivery (eg, subcutaneous routes). The challenge of inhibitors can be overcome with molecules with reduced or even absent immunogenicity or through highly efficacious bypassing activity. 11 Basic research has provided insights on structure and function characterizations throughout the life cycles of FVIII and FIX including biosynthesis, macromolecular interactions, activation/inactivation, and clearance. Through the study of haemophilia-causing mutations, site-directed mutagenesis, detailed structural models and a wide repertoire of animal models, new bioengineering strategies are helping overcome some of the remaining limitations and challenges of traditional clotting factor concentrates. 12 Bioengineering strategies of biologics that can be applied to FVIII and FIX are summarized in Table 1 . Partnering these bioengineering strategies with improved viral vectors has produced the first wave of successful gene therapy approaches. 13 This study will review past and present bioengineered molecules that are advancing care for haemophilia as well as novel approaches that promise to continue to improve care and outcomes for patients with haemophilia.
| B I OENG INEERING OF F VIII

| B domain-deleted FVIII-the first bioengineered FVIII
Expression of rFVIII and its stability in plasma is limited by several mechanisms as summarized in 
| Codon optimization
The genetic code, a triplet of bases of nucleotides, or codon, encod- Codon usage is thought to determine the elongation rhythm, causing ribosomes to slow down or pause at certain sites, thereby modulating sequential folding events that occur co-translationally. 18, 21 This differential synonymous coding is a secondary code guiding in vivo protein folding, and thus, it should not be surprising that studies sites that would encode novel peptides that could trigger immune reactions or interfere with normal cellular functions. 21 An alternative to codon optimization is codon harmonization, seeking to identify and maintain regions of slow translation thought to be important for protein folding. 21, 23 Codon optimization strategies are not standardized, and it is unlikely that any 2 codon-optimized FVIII or FIX constructs would be identical in sequence. Given the potential adverse impact of the various synonymous mutations, it is therefore critical to characterize fully the biochemical profile of the expressed protein as well as con- They observed that the codon-optimized BDD-FVIII was expressed sevenfold higher, similar to prior experience with another codonoptimized BDD-FVIII, 24 without evidence for a significant effect on its structure and function properties. There were some differences observed for post-translational modifications including N-and Oglycosylation at specific sites and degree of Tyr-1680 sulphation.
They also noted an average specific activity that was 1.5-fold higher than wild-type FVIII and higher ratios of activities as measured by clotting assay or thrombin generation compared to chromogenic assay. They attributed this to the quality of the preparations due to the higher protein concentrations and a higher abundance of single- Subjects demonstrated a consistent correlation of one-stage/chromogenic FVIII activity of 1.65, which would not have been expected based on observations with BDD-rFVIII produced recombinantly in cell lines. 25 Future strategies for codon optimization will be driven by bioinformatics insights that are improving prior databases of codon usage tables 17 and through insights on the potential impacts of rare codon clusters on secondary protein structure.
| Rational bioengineering through targeted mutagenesis
Expression of FVIII in heterologous mammalian cells is about 2-3 orders of magnitude lower than similarly sized proteins. 26 This inefficiency in expression contributes to low yields of recombinant protein production and must also be overcome in order to achieve efficacious plasma levels with haemophilia A gene therapy. Some of the factors that contribute to this inefficiency are summarized in Table 2 and include inefficient expression of the mRNA coupled with misfolding and degradation of a sizeable portion of the primary translation product 26, 27 ; retention of FVIII within the endoplasmic reticulum (ER) through interaction with several ER chap- 
| Bioengineering through comparative biology
Comparative biology is yielding some new insights for targeted bioengineering. Whereas human BDD-FVIII is secreted predominantly as a heterodimer, canine BDD-FVIII is secreted predominantly as a single-chain polypeptide. Canine BDD-FVIII has also been shown to be more stable and has a higher specific activity compared to the human form and that this could be attributed to suboptimal cleavage of the canine BDD-FVIII by furin. 38 Nguyen and colleagues hypothesized that deletion of part or all of the furin cleavage recognition sequence could increase the proportion of single-chain human BDD-FVIII. 39 Two deletion variants were secreted primarily as single-chain forms and had twofold higher procoagulant activity compared to BDD-FVIII when expressed from cell lines and achieved 2-to fourfold higher expression in mouse plasma after AAV vector delivery. In another example of comparative biology, Brown and colleagues used insights from characterization of porcine BDD-FVIII. 40 They generated a human-porcine hybrid designated ET3, consisting of human FVIII sequences within the FVIII A2, C1 and C2 domains and porcine sequences in the A1 domain and the activation peptide-A3 domain.
The overall amino acid sequence substitution represented about 9% of the overall sequence but conferred between 10-and 100-fold improved biosynthesis in cell line expression systems. When packaged into an AAV vector, AAV-ET3 achieved correction of FVIII in haemophilia A mice at lower vector doses than could be achieved with 100% human FVIII sequence constructs.
| Ancestral comparative biology
The bioengineering approaches described thus far are optimiza- pathways. This ASR approach has also yielded insights on ancestral FVIII constructs with enhanced specific activity, stability and altered immune reactivity. Insights from this analysis could lead to targeted modification of FVIII that may yield superior rFVIII versions or gene therapy constructs.
| CHALLENG E S TO B E ADDRE SS ED WITH B I OENG INEERED F VIII CON S TRUC TS
| One-stage/two-stage assay discrepancy
The clinical implementation of BDD-FVIII has not been without some challenges in clinical assays and potency assignment. BDD-FVIII activity may be up to 50% lower in one-stage aPTT assays compared to chromogenic assays. 25, 42 The mechanism for this discrepancy has yet to be fully explained. There may be subtle conformational changes resulting from the B domain deletion that alter phospholipid interactions. 43, 44 The potency estimation of BDD-FVIII is sensitive to factor X activation in the chromogenic assay with discrepancies noted between various chromogenic assay kits. There may also be differences in the profile of FVIII activation by thrombin within each of the 2 types of assays that contribute to the discrepancy between BDD-FVIII and full-length FVIII. This discrepancy can be abrogated by altering the composition of the source phospholipid such that phosphatidylserine content is maintained below 10%. In 2003, due to these assay discrepancies and effects on potency assignment, a commercial BDD-FVIII (Xyntha/ReFacto AF, Pfizer, Boston, USA) was reformulated with 20% more drug product than the original formulation to achieve the stated potency. 45 Calibration of the onestage assay with a product-specific standard has also been recommended. 25 However, this has not eliminated some patient-specific factors that can contribute to discrepancy when assaying postinfusion plasma samples. 46 Recombinant FVIII single chain (Afstyla, CSL Behring, Marburg, Germany) is a novel B domain truncated rFVIII in which the heavy and light chains of FVIII are covalently fused to achieve a single polypeptide protein. 47, 48 Following thrombin activation, it is structurally and functionally indistinguishable from endogenously generated FVIIIa. However, it too demonstrates assay discrepancy measuring about 50% lower by one-stage assay compared to chromogenic assay (which is used for its potency assignment). A laboratory field study demonstrated consistent and predictable differences in the assay results across laboratories and FVIII plasma concentrations allowing for a "correction factor" of 2 applied to the one-stage assay results in order to align with chromogenic assay results. 
| Unfolded protein response
The ER, as the site of folding and disulphide bond formation for nascent secreted proteins, is a unique oxidating environment. The UPR is an adaptive signalling pathway that serves to prevent the accumulation of misfolded proteins within the ER and to minimize the stress of oxidative protein folding. 
| Rapid clearance of FVIII from circulation
Although bioengineering has produced EHL-rFIX products with 3-to 5-fold half-life extension, EHL-rFVIII products have been limited to about 1.3-to 1.5-fold that of standard rFVIII. 58 This is likely due to their continued interaction with endogenous VWF where they are subject to clearance as part of the FVIII-VWF complex. 59 Novel bioengineering strategies are attempting to overcome this "ceiling" effect. A VWF-albumin fusion protein exhibits a significant prolongation of VWF half-life in vivo. 60 However, as long as FVIII can dis- from the need for regular FIX prophylaxis). 68 Nevertheless, the continued problem of a cytotoxic response has precluded simply delivering higher doses of vector to target higher plasma levels of FIX.
The current wave of clinical trials for gene therapy is all benefitting from use of a bioengineered FIX construct with higher specific activity. Although these trials have applied some additional improvements in vector design and immunomodulation, the most impactful innovation has been the use of a point mutation (R338L) in FIX. This is a naturally occurring FIX mutation described originally by Simioni et al 69 
| Bioengineered FIX for subcutaneous delivery
Not all bioengineering strategies with FIX are being applied only to gene therapy constructs. You et al 72 Modelling from the preclinical studies suggests that subjects should be able to maintain normal plasma levels of FIX with a daily subcutaneous administration.
| CON CLUS IONS
The current wave of recombinant therapeutics for haemophilia has seen the benefits of bioengineering, leading to EHL factor products, enhanced specific activity to improve the efficacy and safety of gene therapy and introduced the first non-factor therapeutic, a bispecific antibody. Even the current novel products will likely be supplanted through additional bioengineering efforts to further enhance pharmacokinetic profiles, reduce the immunogenicity of factor VIII and even improve on the efficacy of bispecific antibodies as a factor VIIIa-mimetic. The next wave of therapeutics may be influenced from new insights from analyses of next-generation sequencing and transcriptome databases that hope to elucidate new targets for bioengineering.
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